Oggetto:
“A
phase 3, multicentre, open-label, randomized controlled study to
compare the efficacy and safety of Sotrovimab (Xevudy®) or
Tixagevimab and Cilgavimab (Evusheld®) or Nirmatrelvir co-packaged
with Ritonavir (Paxlovid®) in preventing clinical worsening in
COVID-19 home patients at high risk of hospitalization” (titolo
breve: MAI COVID19),
da svolgersi presso il Dipartimento di Cure
Primarie